Charles Schwab Investment Management Inc Insmed Inc Transaction History

Charles Schwab Investment Management Inc

$515 Billion
Q3 2024

A detailed history of Charles Schwab Investment Management Inc transactions in Insmed Inc stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 1,444,266 shares of INSM stock, worth $112 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

1,444,266

Previous 1,306,596 10.54%

Holding current value

$112 Million

Previous $87.5 Million 20.44%

% of portfolio

0.02%

Previous 0.02%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$62.0 - $79.01 $8.54 Million - $10.9 Million	137,670 Added 10.54%	1,444,266 $105 Million
Q2 2024 Aug 12, 2024	BUY	$22.0 - $69.71 $3.96 Million - $12.5 Million	179,829 Added 15.96%	1,306,596 $87.5 Million
Q1 2024 May 08, 2024	SELL	$25.72 - $29.94 $42,926 - $49,969	-1,669 Reduced 0.15%	1,126,767 $30.6 Million
Q4 2023 Feb 06, 2024	BUY	$23.42 - $31.74 $670,491 - $908,684	28,629 Added 2.6%	1,128,436 $35 Million
Q3 2023 Nov 08, 2023	BUY	$19.86 - $26.93 $1.76 Million - $2.39 Million	88,589 Added 8.76%	1,099,807 $27.8 Million
Q2 2023 Aug 09, 2023	BUY	$16.44 - $21.1 $84,698 - $108,707	5,152 Added 0.51%	1,011,218 $21.3 Million
Q1 2023 May 11, 2023	SELL	$16.26 - $21.73 $6,357 - $8,496	-391 Reduced 0.04%	1,006,066 $17.2 Million
Q4 2022 Feb 13, 2023	BUY	$16.98 - $23.15 $2.31 Million - $3.15 Million	136,230 Added 15.65%	1,006,457 $20.1 Million
Q3 2022 Nov 14, 2022	BUY	$20.88 - $28.21 $408,538 - $551,956	19,566 Added 2.3%	870,227 $18.7 Million
Q2 2022 Aug 15, 2022	SELL	$17.07 - $25.71 $154,517 - $232,726	-9,052 Reduced 1.05%	850,661 $16.8 Million
Q1 2022 May 13, 2022	BUY	$20.42 - $28.13 $207,038 - $285,210	10,139 Added 1.19%	859,713 $20.2 Million
Q4 2021 Feb 11, 2022	BUY	$25.89 - $33.45 $533,877 - $689,772	20,621 Added 2.49%	849,574 $23.1 Million
Q3 2021 Nov 16, 2021	BUY	$22.46 - $29.47 $722,201 - $947,607	32,155 Added 4.04%	828,953 $22.8 Million
Q2 2021 Aug 16, 2021	BUY	$24.17 - $36.01 $1.55 Million - $2.31 Million	64,281 Added 8.78%	796,798 $22.7 Million
Q1 2021 May 17, 2021	SELL	$32.28 - $44.3 $355,047 - $487,255	-10,999 Reduced 1.48%	732,517 $25 Million
Q4 2020 Feb 16, 2021	BUY	$31.45 - $40.54 $1.41 Million - $1.82 Million	44,952 Added 6.43%	743,516 $24.8 Million
Q3 2020 Nov 13, 2020	BUY	$26.0 - $34.5 $701,402 - $930,706	26,977 Added 4.02%	698,564 $22.5 Million
Q2 2020 Aug 14, 2020	BUY	$14.11 - $29.42 $1.61 Million - $3.36 Million	114,371 Added 20.53%	671,587 $18.5 Million
Q1 2020 May 15, 2020	BUY	$13.63 - $33.98 $144,777 - $360,935	10,622 Added 1.94%	557,216 $8.93 Million
Q4 2019 Feb 07, 2020	BUY	$16.12 - $24.98 $182,929 - $283,473	11,348 Added 2.12%	546,594 $13.1 Million
Q3 2019 Nov 08, 2019	BUY	$15.49 - $25.78 $699,745 - $1.16 Million	45,174 Added 9.22%	535,246 $9.44 Million
Q2 2019 Aug 09, 2019	BUY	$23.0 - $32.19 $1.09 Million - $1.52 Million	47,353 Added 10.7%	490,072 $12.5 Million
Q1 2019 May 14, 2019	BUY	$13.91 - $31.15 $325,299 - $728,473	23,386 Added 5.58%	442,719 $12.9 Million
Q4 2018 Feb 14, 2019	BUY	$11.6 - $18.7 $18,490 - $29,807	1,594 Added 0.38%	419,333 $5.5 Million
Q3 2018 Nov 13, 2018	BUY	$18.95 - $28.08 $333,690 - $494,460	17,609 Added 4.4%	417,739 $8.45 Million
Q2 2018 Aug 08, 2018	BUY	$20.0 - $29.72 $373,720 - $555,347	18,686 Added 4.9%	400,130 $9.46 Million
Q1 2018 May 07, 2018	BUY	$21.69 - $32.99 $429,071 - $652,608	19,782 Added 5.47%	381,444 $8.59 Million
Q4 2017 Jan 17, 2018	BUY	$26.43 - $31.78 $366,425 - $440,597	13,864 Added 3.99%	361,662 $11.3 Million
Q3 2017 Nov 13, 2017	BUY	$11.61 - $31.21 $4.04 Million - $10.9 Million	347,798	347,798 $10.9 Million

Others Institutions Holding INSM

# of Institutions

478

Shares Held

180M

Call Options Held

2.27M

Put Options Held

3.33M

View Full List

About INSMED Inc

Ticker INSM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 135,476,992
Market Cap $10.5B
Description
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversibl...

More about INSM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.

Account

Charles Schwab Investment Management Inc Insmed Inc Transaction History